Nasopharyngeal Carcinoma - 33 Studies Found
| Active, not recruiting |
: Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma : Nasopharyngeal Carcinoma : 2006-09-20 :
|
| Active, not recruiting |
: Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma : Nasopharyngeal Carcinoma : 2010-11-22 :
|
| Terminated |
: A Phase III Study of Radiotherapy With or Without Adjuvant C/T in Advanced Stage Nasopharyngeal Carcinoma Patients : Nasopharyngeal Carcinoma : 2005-09-13 : Drug: Cisplatin,5-FU,Leucovorin |
| Active, not recruiting |
: Positron Emission Tomography Scanning and Epstein-Barr Virus DNA Levels in the Staging and Follow-up of Nasopharyngeal Carcinoma. : Nasopharyngeal Carcinoma : 2005-09-09 |
| Active, not recruiting |
: Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma : Nasopharyngeal Carcinoma : 2008-05-09 :
|
| NOT_YET_RECRUITING |
: Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer : : 2025-08-02 : Undergo collection of blood samples |
| NOT_YET_RECRUITING |
: Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma : : 2025-08-02 : 10mg/kg administered intravenously (IV) |
| Completed |
: Bacterial Decolonization to Prevent Radiation-induced Oral Mucositis : : 2025-08-02 : Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the n |
| NOT_YET_RECRUITING |
: Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy : : 2025-08-02 : Enteral immunonutrition (Oral Impact�, Nestle), 250ml/ bottle, 2 bottles per day, from 5 days before radiotherapy to the end of radiotherapy. |
| Completed |
: Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma : Nasopharyngeal Carcinoma : 2025-08-02 : nimotuzumab 200mg/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT |